This study is testing a new treatment for certain types of cervical cancer to see if it's safe and effective. The treatment combines a drug called **AK104** with chemotherapy drugs **nab-paclitaxel** and **carboplatin**. These drugs are given before surgery to help shrink the cancer and preserve fertility. **Key Points:** - **Eligibility:** Women aged 18-45 with specific types of cervical cancer (stage IB2-IB3) who want to preserve fertility. Participants cannot have received previous treatments like chemotherapy or radiation for cervical cancer. - **Study Process:** Participants must agree to regular visits, provide tumor and blood samples, and follow the study's treatment plan. Important health tests will be conducted to ensure participants are fit for the study. - **Risks and Considerations:** Participants must avoid becoming pregnant during the study and use effective birth control. Women with certain health issues or other cancer treatments in the past three years are excluded. This study seeks to improve the treatment outcomes for young women with cervical cancer while allowing them to maintain their ability to have children in the future.